Logo image of GERN

GERON CORP (GERN) Stock Fundamental Analysis

NASDAQ:GERN - Nasdaq - US3741631036 - Common Stock - Currency: USD

1.54  -0.06 (-3.75%)

After market: 1.53 -0.01 (-0.65%)

Fundamental Rating

3

Taking everything into account, GERN scores 3 out of 10 in our fundamental rating. GERN was compared to 559 industry peers in the Biotechnology industry. While GERN seems to be doing ok healthwise, there are quite some concerns on its profitability. GERN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year GERN has reported negative net income.
In the past year GERN has reported a negative cash flow from operations.
GERN had negative earnings in each of the past 5 years.
In the past 5 years GERN always reported negative operating cash flow.
GERN Yearly Net Income VS EBIT VS OCF VS FCFGERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

GERN has a Return On Assets of -24.72%. This is in the better half of the industry: GERN outperforms 73.52% of its industry peers.
GERN has a better Return On Equity (-51.83%) than 64.94% of its industry peers.
Industry RankSector Rank
ROA -24.72%
ROE -51.83%
ROIC N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
GERN Yearly ROA, ROE, ROICGERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 97.88%, GERN belongs to the top of the industry, outperforming 97.85% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for GERN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GERN Yearly Profit, Operating, Gross MarginsGERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

4

2. Health

2.1 Basic Checks

GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
GERN has more shares outstanding than it did 1 year ago.
GERN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GERN has an improved debt to assets ratio.
GERN Yearly Shares OutstandingGERN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GERN Yearly Total Debt VS Total AssetsGERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

GERN has an Altman-Z score of -2.04. This is a bad value and indicates that GERN is not financially healthy and even has some risk of bankruptcy.
GERN has a Altman-Z score (-2.04) which is comparable to the rest of the industry.
GERN has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.44, GERN is doing worse than 72.99% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -2.04
ROIC/WACCN/A
WACC9.47%
GERN Yearly LT Debt VS Equity VS FCFGERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

GERN has a Current Ratio of 7.87. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GERN (7.87) is better than 69.59% of its industry peers.
A Quick Ratio of 6.97 indicates that GERN has no problem at all paying its short term obligations.
GERN has a better Quick ratio (6.97) than 66.91% of its industry peers.
Industry RankSector Rank
Current Ratio 7.87
Quick Ratio 6.97
GERN Yearly Current Assets VS Current LiabilitesGERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.00% over the past year.
GERN shows a strong growth in Revenue. In the last year, the Revenue has grown by 22393.81%.
The Revenue has been growing by 178.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)22393.81%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%12927.3%

3.2 Future

Based on estimates for the next years, GERN will show a very strong growth in Earnings Per Share. The EPS will grow by 40.11% on average per year.
Based on estimates for the next years, GERN will show a very strong growth in Revenue. The Revenue will grow by 64.14% on average per year.
EPS Next Y51.86%
EPS Next 2Y40.27%
EPS Next 3Y35.79%
EPS Next 5Y40.11%
Revenue Next Year163.93%
Revenue Next 2Y102.27%
Revenue Next 3Y82.26%
Revenue Next 5Y64.14%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GERN Yearly Revenue VS EstimatesGERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
GERN Yearly EPS VS EstimatesGERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GERN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GERN Price Earnings VS Forward Price EarningsGERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GERN Per share dataGERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

GERN's earnings are expected to grow with 35.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.27%
EPS Next 3Y35.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GERN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GERON CORP

NASDAQ:GERN (6/11/2025, 5:56:41 PM)

After market: 1.53 -0.01 (-0.65%)

1.54

-0.06 (-3.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners81.67%
Inst Owner Change4.26%
Ins Owners0.09%
Ins Owner Change16.95%
Market Cap980.86M
Analysts81.33
Price Target3.76 (144.16%)
Short Float %10.56%
Short Ratio5.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.86%
Min EPS beat(2)13.34%
Max EPS beat(2)22.38%
EPS beat(4)4
Avg EPS beat(4)23.71%
Min EPS beat(4)5.99%
Max EPS beat(4)53.15%
EPS beat(8)7
Avg EPS beat(8)16.86%
EPS beat(12)10
Avg EPS beat(12)17.48%
EPS beat(16)12
Avg EPS beat(16)13.8%
Revenue beat(2)1
Avg Revenue beat(2)-8.7%
Min Revenue beat(2)-19.48%
Max Revenue beat(2)2.07%
Revenue beat(4)3
Avg Revenue beat(4)60.74%
Min Revenue beat(4)-19.48%
Max Revenue beat(4)214.6%
Revenue beat(8)5
Avg Revenue beat(8)174.75%
Revenue beat(12)6
Avg Revenue beat(12)123.62%
Revenue beat(16)10
Avg Revenue beat(16)199.78%
PT rev (1m)-10.61%
PT rev (3m)-18.06%
EPS NQ rev (1m)-10.84%
EPS NQ rev (3m)5.91%
EPS NY rev (1m)-22.02%
EPS NY rev (3m)-70.19%
Revenue NQ rev (1m)-14.75%
Revenue NQ rev (3m)-14.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-32.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.43
P/FCF N/A
P/OCF N/A
P/B 3.66
P/tB 3.66
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0.18
BVpS0.42
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.72%
ROE -51.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.88%
FCFM N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.87
Quick Ratio 6.97
Altman-Z -2.04
F-Score4
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)94.77%
Cap/Depr(5y)125.95%
Cap/Sales(3y)140.92%
Cap/Sales(5y)119.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y51.86%
EPS Next 2Y40.27%
EPS Next 3Y35.79%
EPS Next 5Y40.11%
Revenue 1Y (TTM)22393.81%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%12927.3%
Revenue Next Year163.93%
Revenue Next 2Y102.27%
Revenue Next 3Y82.26%
Revenue Next 5Y64.14%
EBIT growth 1Y36.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year74.41%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-45.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.19%
OCF growth 3YN/A
OCF growth 5YN/A